RSS feed (help and list of feeds)
Notification
Search for previous notification documents
-
Title January Tender Notification (2 pages, 101 KB) Contact Notifications Email 
Notifications@pharmac.govt.nz
-
Title December Tender Notification (4 pages, 110 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Sole Supply of Metoprolol Succinate and Metoprolol Tartrate (3 pages, 126 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Candesartan tab 32 mg - weight rule change (2 pages, 133 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Changes to 230 ml spacer device (1 page, 90 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Candesartan - Access Widening and Sole Supply (3 pages, 129 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Deferral of sole supply - Clarithromycin (1 page, 132 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title November Tender Notification (4 pages, 112 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Approval of proposal for sole supply of Respiratory Devices (3 pages, 157 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Approval of proposal to re-apply reference pricing across brands of risperidone and quetiapine (2 pages, 110 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Notification on CSL ACP involving multiple products (3 pages, 129 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Title Notification for efavirenz (Stocrin) (1 page, 103 KB) Contact Greg Williams Email Greg.Williams@pharmac.govt.nz
-
Title Release of 2011/12 Invitation to Tender (5 pages, 140 KB) Contact Marcus Kim Email Marcus.Kim@pharmac.govt.nz
-
Title Notification on Allergan ACP (2 pages, 49 KB) Contact Sueanne Yee Email Sueanne.Yee@pharmac.govt.nz
-
Title October Tender Notification (4 pages, 115 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Ovestin - Removal of close control (2 pages, 145 KB)
-
Changes to General Rules of the Pharmaceutical Schedule (2 pages, 106 KB)
-
Removal of Close Control for Ovestin (oestriol) (2 pages, 145 KB)
-
Title Lignocaine urethral syringe endorsement decision (1 page, 100 KB) Contact Notifications Email Notifications@pharmac.govt.nz
-
Changes to funding and access of some asthma products (4 pages, 138 KB)
Page updated on 01 Feb 2012
Linked documents
January Tender Notification; Contact: Notifications (2 pages, 101 KB)
31 January 2012 TENDER RESULTS The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award a tender for Sole Subsidised Supply Status for a product included in the 2010/11 Invitation to Tender, dated 2 November 2010.…
December Tender Notification; Contact: Notifications (4 pages, 110 KB)
22 December 2011 TENDER RESULTS The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated…
Sole Supply of Metoprolol Succinate and Metoprolol Tartrate; Contact: Notifications (3 pages, 126 KB)
6 December 2011 Sole Supply of Metoprolol Succinate and Metoprolol Tartrate The PHARMAC Board has approved sole supply proposals for metoprolol succinate (tablets) and metoprolol tartrate (tablets and injection). In summary, the decisions will mean that: Metoprolol succinate tablets…
Candesartan tab 32 mg - weight rule change; Contact: Notifications (2 pages, 133 KB)
FACSIMILE To All New Zealand Pharmacies, IPA Pharmacy Facilitators and Wholesalers PHARMAC Candesartan tab 32 mg – weight rule change and Medicines Regulation Changes relating to Dental Prescriptions 2 December 2011 2 From Subject Date Pages Dear Pharmacist / Wholesaler…
Changes to 230 ml spacer device; Contact: Notifications (1 page, 90 KB)
1 December 2011 Dear Health Professional Change in the brand of Spacer Device subsidised – effective 1 December 2011. Between December 2011 and February 2012 there will be a change in the 230 ml spacer device used with pressurised metered…
Candesartan - Access Widening and Sole Supply; Contact: Notifications (3 pages, 129 KB)
30 November 2011 Candesartan – Access Widening and Sole Supply The PHARMAC Board has approved a proposal to widen the candesartan Special Authority access criteria and to have candesartan supplied under a Sole Supply arrangement. In summary, the decisions will…
Deferral of sole supply - Clarithromycin; Contact: Notifications (1 page, 132 KB)
FACSIMILE To Fax From Subject All New Zealand Pharmacies, IPA Pharmacy Facilitators and Wholesalers Autodial Rebecca Bloor, Schedule Analyst Clarithromycin 500 mg tablets – Deferral of Sole Supply and Hospital Sole Supply Pages 1 Date 30 November 2011 Dear…
November Tender Notification; Contact: Notifications (4 pages, 112 KB)
30 November 2011 TENDER RESULTS The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated…
Approval of proposal for sole supply of Respiratory Devices; Contact: Notifications (3 pages, 157 KB)
15 November 2011 Sole supply of Respiratory Devices (peak flow meters, spacer devices, paediatric masks) PHARMAC is pleased to announce the approval of proposals with Air Flow Products Limited and GlaxoSmithKline NZ Limited for the sole supply of a number…
Approval of proposal to re-apply reference pricing across brands of risperidone and quetiapine; Contact: Notifications (2 pages, 110 KB)
7 November 2011 Approval of proposal to re-apply reference pricing across brands of risperidone and quetiapine PHARMAC has approved a proposal to re-apply reference pricing across different brands of risperidone tablets and oral liquid and across different brands of quetiapine…
Notification on CSL ACP involving multiple products; Contact: Notifications (3 pages, 129 KB)
3 November 2011 Proposal relating to betamethasone diproprionate with calcipotriol, calcipotriol, fusidic acid and bumetanide approved PHARMAC is pleased to announce the approval of an agreement with CSL Biotherapies (NZ) Limited. This was the subject of a consultation letter dated…
Notification for efavirenz (Stocrin); Contact: Greg Williams (1 page, 103 KB)
3 November 2011 Approval of proposal to amend the terms of listing for efavirenz (Stocrin) PHARMAC is pleased to announce the approval of an agreement with Merck Sharp and Dohme (New Zealand) Limited (MSD) for efavirenz (Stocrin). This was the…
Release of 2011/12 Invitation to Tender; Contact: Marcus Kim (5 pages, 140 KB)
2 November 2011 Release of the 2011/12 Invitation to Tender The 2011/12 Invitation to Tender (2011/12 ITT) has been approved by the PHARMAC Board and has been distributed today via the electronic tender (eTender) system. If you do not receive…
Notification on Allergan ACP; Contact: Sueanne Yee (2 pages, 49 KB)
1 November 2011 Approval of proposal to amend the terms of listing for bimatoprost, brimonidine tartrate with timolol maleate and prednisolone acetate PHARMAC is pleased to announce the approval of an agreement with Allergan Australia Pty Ltd for four ophthalmological…
October Tender Notification; Contact: Notifications (4 pages, 115 KB)
31 October 2011 TENDER RESULTS The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2…
Ovestin - Removal of close control (2 pages, 145 KB)
FACSIMILE To All New Zealand Pharmacies, IPA Pharmacy Facilitators and Wholesalers PHARMAC Oestriol cream and pessaries– removal of pharmacist endorsed Close Control 27 October 2011 2 From Subject Date Pages Dear Pharmacist / Wholesaler Due to stock shortages, PHARMAC implemented…
Changes to General Rules of the Pharmaceutical Schedule (2 pages, 106 KB)
27 October 2011 Changes to General Rules in the Pharmaceutical Schedule PHARMAC is pleased to announce amendments to the General Rules of the Pharmaceutical Schedule from 1 November 2011. This proposal was the subject of a consultation letter dated 19…
Removal of Close Control for Ovestin (oestriol) (2 pages, 145 KB)
FACSIMILE To All New Zealand Pharmacies, IPA Pharmacy Facilitators and Wholesalers PHARMAC Oestriol cream and pessaries– removal of pharmacist endorsed Close Control 27 October 2011 2 From Subject Date Pages Dear Pharmacist / Wholesaler Due to stock shortages, PHARMAC implemented…
Lignocaine urethral syringe endorsement decision; Contact: Notifications (1 page, 100 KB)
26 October 2011 Approval of proposal to amend the access criteria for lignocainecontaining urethral syringes PHARMAC has approved a proposal to add an endorsement restriction to the listings of lignocaine gel 2%, 10 ml urethral syringe (Pfizer) and lignocaine gel…
Changes to funding and access of some asthma products (4 pages, 138 KB)
21 October 2011 Approval of proposal on subsidy changes for some respiratory inhalation products and access restrictions to combination inhalers The following proposals have been approved: Removal of the requirement for patients to be on separate ICS and LABA…
